Cel-Sci Corp (AMEX:CVM) (was HIV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV)

CVM 5.440

-6.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul K who wrote (2822)	5/26/2000 12:31:00 PM
From: Paul K	Read Replies (1) of 2836

CEL-SCI Corporation Reports Financial Results VIENNA, Va., May 15 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM; Berlin/Frankfurt Stock Exchanges:LSR) reports financial results for the six months ending March 31, 2000. Revenues were $135,848 in the first six months of fiscal 2000 compared to $290,643 in the first six months of fiscal 1999. Revenues are almost entirely derived from interest income accrued from investments. The loss from operations for the first six months of fiscal 2000 was $4.56 million versus $3.64 million in fiscal 1999. Research and development (R&D) expenses increased from $2.2 million in the first six months in fiscal 1999 to $2.5 million in the first six months of fiscal 2000. R&D expenses were increased during the most recent 6 months because the Company is involved in more clinical trials. General and administrative expenses rose from $1.55 million to $2.07 million during the same time periods due to a non-cash charge to expense for the issuance of common stock. The balance sheet reflects $15.7 million in cash and investments. Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We are very pleased with the results from our human clinical trials in the treatment of cancer. Between 50% and 100% of the cancer patients in our studies have responded with tumor regressions, depending on the dose, frequency and route of administration. Our cash position allows us to aggressively pursue the development of our cancer product Multikine(TM)."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next